TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Medical Developments International Limited ( (AU:MVP) ) is now available.
At the 2025 Annual General Meeting, MVP’s Chair, Gordon Naylor, announced his departure with Mark Fladrich set to assume the role in December. The company reported a significant improvement in its financials for FY25, with an 18% increase in revenue and a modest net profit after tax. MVP plans to deploy recently raised funds to support its growth strategy, while also enhancing governance and management systems. The transition in leadership is expected to bring fresh perspectives, crucial for the company’s continued growth.
The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.
More about Medical Developments International Limited
Medical Developments International Ltd (MVP) is an Australian company specializing in emergency medical solutions, including pain relief and respiratory products. The company is known for manufacturing Penthrox, a non-opioid trauma and emergency pain relief product, approved for use in various medical settings in Australia.
Average Trading Volume: 152,793
Technical Sentiment Signal: Sell
Current Market Cap: A$68.16M
See more data about MVP stock on TipRanks’ Stock Analysis page.